1506 related articles for article (PubMed ID: 16504026)
1. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
Haro JM; Novick D; Suarez D; Roca M
J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
[TBL] [Abstract][Full Text] [Related]
4. Risperidone versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S
Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.
Faries D; Ascher-Svanum H; Zhu B; Correll C; Kane J
BMC Psychiatry; 2005 May; 5():26. PubMed ID: 15921508
[TBL] [Abstract][Full Text] [Related]
6. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
7. The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain.
Ciudad A; Haro JM; Alonso J; Bousoño M; Suárez D; Novick D; Gilaberte I
Eur Psychiatry; 2008 Jan; 23(1):1-7. PubMed ID: 18023154
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
9. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Rosenheck RA; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
Am J Psychiatry; 2006 Apr; 163(4):611-22. PubMed ID: 16585435
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
Carpiniello B; Mellino G; Pintore S; Puddu L; Pinna F
Clin Ter; 2011; 162(4):331-41. PubMed ID: 21912821
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
McEvoy JP; Lieberman JA; Stroup TS; Davis SM; Meltzer HY; Rosenheck RA; Swartz MS; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
Am J Psychiatry; 2006 Apr; 163(4):600-10. PubMed ID: 16585434
[TBL] [Abstract][Full Text] [Related]
13. Clozapine versus other atypical antipsychotics for schizophrenia.
Asenjo Lobos C; Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Leucht S
Cochrane Database Syst Rev; 2010 Nov; (11):CD006633. PubMed ID: 21069690
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
15. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
[TBL] [Abstract][Full Text] [Related]
16. The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire.
Hodgson R; Belgamwar R; Al-tawarah Y; MacKenzie G
Hum Psychopharmacol; 2005 Mar; 20(2):141-7. PubMed ID: 15651052
[TBL] [Abstract][Full Text] [Related]
17. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
18. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Soares-Weiser K; Béchard-Evans L; Lawson AH; Davis J; Ascher-Svanum H
Eur Neuropsychopharmacol; 2013 Feb; 23(2):118-25. PubMed ID: 22633617
[TBL] [Abstract][Full Text] [Related]
19. Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
Zhu B; Ascher-Svanum H; Faries DE; Correll CU; Kane JM
BMC Psychiatry; 2008 Apr; 8():19. PubMed ID: 18394168
[TBL] [Abstract][Full Text] [Related]
20. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
